While the scramble for a COVID-19 vaccine has already borne fruit, making sure the supply is enough and the vaccines are widely distributed is another matter altogether.
Local pharmaceutical company Glovax Biotech, which produces low-cost vaccines, is in discussion with the Department of Trade and Industry (DTI) and the Bureau of Investments to potentially construct a COVID-19 vaccine plant in the Philippines.
Glovax Biotech is looking at being able to produce the next generation vaccine in partnership with Korean WHO pre-qualified vaccine manufacturers Eubiologics and LG Chem. The next generation vaccine can potentially protect against newer strains and mutations of coronavirus.
The vaccine plant will cost approximately P7 billion to build. Once constructed, it will be able to produce 40 million doses of the COVID-19 vaccine for local use. It can also facilitate the more efficient production of vaccines in the event of future pandemics.